Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.52
PLX's Cash-to-Debt is ranked lower than
86% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. PLX: 0.52 )
Ranked among companies with meaningful Cash-to-Debt only.
PLX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.41  Med: No Debt Max: No Debt
Current: 0.52
Equity-to-Asset -0.43
PLX's Equity-to-Asset is ranked lower than
95% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PLX: -0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
PLX' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.15  Med: -0.12 Max: 0.8
Current: -0.43
-1.15
0.8
Debt-to-Equity -2.45
PLX's Debt-to-Equity is ranked lower than
99.99% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. PLX: -2.45 )
Ranked among companies with meaningful Debt-to-Equity only.
PLX' s Debt-to-Equity Range Over the Past 10 Years
Min: -9.07  Med: -1.04 Max: 27.25
Current: -2.45
-9.07
27.25
Debt-to-EBITDA -1.18
PLX's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. PLX: -1.18 )
Ranked among companies with meaningful Debt-to-EBITDA only.
PLX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.69  Med: -3.04 Max: -1.18
Current: -1.18
-4.69
-1.18
Piotroski F-Score: 4
Altman Z-Score: -8.07
Beneish M-Score: -1.88
WACC vs ROIC
12.72%
-921.20%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -178.50
PLX's Operating Margin % is ranked lower than
57% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. PLX: -178.50 )
Ranked among companies with meaningful Operating Margin % only.
PLX' s Operating Margin % Range Over the Past 10 Years
Min: -8239.43  Med: -542.39 Max: -35.36
Current: -178.5
-8239.43
-35.36
Net Margin % -385.91
PLX's Net Margin % is ranked lower than
65% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. PLX: -385.91 )
Ranked among companies with meaningful Net Margin % only.
PLX' s Net Margin % Range Over the Past 10 Years
Min: -8103.09  Med: -436.59 Max: 1329.9
Current: -385.91
-8103.09
1329.9
ROA % -105.56
PLX's ROA % is ranked lower than
84% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. PLX: -105.56 )
Ranked among companies with meaningful ROA % only.
PLX' s ROA % Range Over the Past 10 Years
Min: -105.56  Med: -34.11 Max: 66.1
Current: -105.56
-105.56
66.1
ROC (Joel Greenblatt) % -659.42
PLX's ROC (Joel Greenblatt) % is ranked lower than
54% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. PLX: -659.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PLX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -988.83  Med: -224.15 Max: -67
Current: -659.42
-988.83
-67
3-Year EBITDA Growth Rate -20.60
PLX's 3-Year EBITDA Growth Rate is ranked lower than
76% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. PLX: -20.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PLX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -53.3  Med: -11.95 Max: 83
Current: -20.6
-53.3
83
3-Year EPS without NRI Growth Rate -8.60
PLX's 3-Year EPS without NRI Growth Rate is ranked lower than
60% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. PLX: -8.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PLX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -49.3  Med: -7.2 Max: 54.6
Current: -8.6
-49.3
54.6
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PLX's 30-Y Financials

Financials (Next Earnings Date: 2018-03-16)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

PLX Guru Trades in Q4 2016

Jim Simons 479,300 sh (+164.95%)
» More
Q1 2017

PLX Guru Trades in Q1 2017

Jim Simons 1,927,500 sh (+302.15%)
» More
Q2 2017

PLX Guru Trades in Q2 2017

Jim Simons 2,300,800 sh (+19.37%)
» More
Q3 2017

PLX Guru Trades in Q3 2017

Jim Simons 2,101,300 sh (-8.67%)
» More
» Details

Insider Trades

Latest Guru Trades with AMEX:PLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:TSXV:EMC, XKLS:7178, NAS:ZFGN, NAS:ALDX, TSXV:ABCN, ASX:MDC, NAS:EIGR, OSTO:BINV, NAS:NOVN, XCNQ:CRZ, ROCO:4726, OSTO:NUE, ROCO:8279, NAS:PRQR, XKRX:011000, XPAR:ALONC, ROCO:6589, NAS:TRVN, XKRX:228760, OSTO:ISOFOL » details
Traded in other countries:PBD.Germany, PLX.Israel,
Headquarter Location:Israel
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx.

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx.

Top Ranked Articles about Protalix BioTherapeutics Inc

Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 for the Treatment of Fabry Disease in the European Union
Protalix BioTherapeutics to Hold Third Quarter 2017 Financial Results and Corporate Update Conference Call on November 8, 2017
Protalix BioTherapeutics Enters into an Exclusive Ex-US Partnership with Chiesi Farmaceutici for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
Protalix Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Protalix BioTherapeutics to Hold Second Quarter 2017 Financial Results and Corporate Update Conference Call on August 9, 2017
Protalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018 for $8.55 million Notes Maturing February 2022
Protalix BioTherapeutics Announces Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis Presented at the 40th European Cystic Fibrosis Society Conference
Protalix BioTherapeutics Announces FDA Approval to Operate its Current Facility as a Multi-Product Facility
Protalix BioTherapeutics to Present at the Jefferies 2017 Global Healthcare Conference
Protalix BioTherapeutics Announces Presentation of Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference

Ratios

vs
industry
vs
history
PS Ratio 5.26
PLX's PS Ratio is ranked higher than
72% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. PLX: 5.26 )
Ranked among companies with meaningful PS Ratio only.
PLX' s PS Ratio Range Over the Past 10 Years
Min: 3.26  Med: 41.36 Max: 1618
Current: 5.26
3.26
1618
EV-to-EBIT -2.29
PLX's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. PLX: -2.29 )
Ranked among companies with meaningful EV-to-EBIT only.
PLX' s EV-to-EBIT Range Over the Past 10 Years
Min: -51  Med: -11.7 Max: -1.8
Current: -2.29
-51
-1.8
EV-to-EBITDA -2.35
PLX's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. PLX: -2.35 )
Ranked among companies with meaningful EV-to-EBITDA only.
PLX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -81.6  Med: -12.8 Max: -1.9
Current: -2.35
-81.6
-1.9
EV-to-Revenue 6.81
PLX's EV-to-Revenue is ranked higher than
67% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. PLX: 6.81 )
Ranked among companies with meaningful EV-to-Revenue only.
PLX' s EV-to-Revenue Range Over the Past 10 Years
Min: 5  Med: 39.95 Max: 1439
Current: 6.81
5
1439
Current Ratio 1.92
PLX's Current Ratio is ranked lower than
66% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. PLX: 1.92 )
Ranked among companies with meaningful Current Ratio only.
PLX' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 4.79 Max: 91.65
Current: 1.92
1.02
91.65
Quick Ratio 1.64
PLX's Quick Ratio is ranked lower than
67% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. PLX: 1.64 )
Ranked among companies with meaningful Quick Ratio only.
PLX' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 4.79 Max: 91.65
Current: 1.64
0.96
91.65
Days Inventory 148.27
PLX's Days Inventory is ranked lower than
59% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. PLX: 148.27 )
Ranked among companies with meaningful Days Inventory only.
PLX' s Days Inventory Range Over the Past 10 Years
Min: 24.15  Med: 207.5 Max: 3304.7
Current: 148.27
24.15
3304.7
Days Sales Outstanding 141.17
PLX's Days Sales Outstanding is ranked lower than
51% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. PLX: 141.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
PLX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.95  Med: 168.97 Max: 2016.91
Current: 141.17
14.95
2016.91
Days Payable 202.97
PLX's Days Payable is ranked higher than
85% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. PLX: 202.97 )
Ranked among companies with meaningful Days Payable only.
PLX' s Days Payable Range Over the Past 10 Years
Min: 174.16  Med: 731.34 Max: 2222.44
Current: 202.97
174.16
2222.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.80
PLX's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. PLX: -9.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PLX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -539.3  Med: -5 Max: 14
Current: -9.8
-539.3
14

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.13
PLX's Price-to-Median-PS-Value is ranked higher than
96% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. PLX: 0.13 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PLX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.58 Max: 31.52
Current: 0.13
0.01
31.52
Earnings Yield (Greenblatt) % -43.76
PLX's Earnings Yield (Greenblatt) % is ranked lower than
87% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. PLX: -43.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PLX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -54.9  Med: -8.55 Max: -2
Current: -43.76
-54.9
-2

More Statistics

Revenue (TTM) (Mil) $18.85
EPS (TTM) $ -0.65
Beta1.63
Short Percentage of Float5.20%
52-Week Range $0.26 - 1.51
Shares Outstanding (Mil)139.73

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 27 48
EPS ($) -0.52 -0.17
EPS without NRI ($) -0.52 -0.17
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}